Indian pharmaceutical company Gland Pharma receives USFDA approval for generic drug Eribulin Mesylate Injection to treat metastatic breast cancer.
Indian pharmaceutical company Gland Pharma has received USFDA approval for its generic drug Eribulin Mesylate Injection, used to treat metastatic breast cancer. The product is expected to be the first generic approval in the market, with sales of around $92 million in the US. Gland Pharma is co-developing several complex injectables, including this product, with Orbicular Pharmaceutical Technologies.
April 08, 2024
8 Articles